Fig. 3From: Potential mechanisms of osthole against bladder cancer cells based on network pharmacology, molecular docking, and experimental validationMolecular docking of ligands and target proteins. A Docking process of osthole, co-crystal ligand with MAPK1 protein. B Docking process of osthole, co-crystal ligand with AKT1 protein. C Docking process of co-crystal ligand with HRAS proteinBack to article page